NCT07136077 2026-02-27
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
12 trialsNCT06358430 2026-01-15
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06287814 2025-07-10
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
University Hospital, Montpellier
Recruiting
NCT05196087 2025-07-02
NIP IT!
University Health Network, Toronto
Recruiting
NCT06111105 2025-03-30
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing CtDNA Diagnostics - Colorectal Cancer
University of Aarhus
Recruiting
NCT05534087 2024-11-29
CLAUDIA
Seoul National University Hospital
Phase 3 Recruiting
NCT05965479 2024-11-12
DECIPHER
University of Southampton
Phase 2 Recruiting
NCT06498752 2024-08-06
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06253650 2024-06-13
TRINITY
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT05952661 2023-07-19
ECMRD-001
Hebei Medical University Fourth Hospital
Recruiting
NCT05867901 2023-05-31
Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence
Peking University People's Hospital
Recruiting
NCT05408897 2022-09-21
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
Peking University People's Hospital
Recruiting